ZNF592 Antibody

What is ZNF592 and what role does it play in cellular pathways?

ZNF592 (Zinc Finger Protein 592) is a 1267-amino-acid zinc-finger (ZnF) protein that functions as a transcription factor. It contains multiple C2H2-type zinc finger domains that enable DNA binding. ZNF592 is thought to play a crucial role in regulating genes involved in cerebellar development . Research findings indicate that ZNF592 may be involved in complex developmental pathways, particularly in the regulation of genes during cerebellar development. Mutations in ZNF592 have been associated with CAMOS (Cerebellar Ataxia with Mental retardation, Optic atrophy and Skin abnormalities), a rare autosomal recessive syndrome .

Expression analysis shows that ZNF592 is ubiquitously expressed in human adult tissues, with higher expression observed in skeletal muscle and notable expression in brain tissues including the cerebellum, cerebellar vermis, and substantia nigra .

What is the predicted molecular weight of ZNF592 and what should I expect on Western blots?

This discrepancy between calculated and observed molecular weights may be due to post-translational modifications, proteolytic processing, or the use of different antibodies targeting various epitopes of the protein .

What applications are ZNF592 antibodies validated for?

ZNF592 antibodies have been validated for multiple research applications as shown in this compilation from various manufacturers:

What species reactivity has been confirmed for ZNF592 antibodies?

The following species reactivity has been confirmed for various commercially available ZNF592 antibodies:

It's important to note that cross-reactivity with other species may be possible but would need to be experimentally verified. For example, a customer inquired about potential cross-reactivity with dog tissues, but this had not been specifically tested .

How can I validate the specificity of a ZNF592 antibody in my experimental system?

To validate the specificity of ZNF592 antibodies, several approaches are recommended:

• Peptide competition assay: Multiple manufacturers demonstrate this technique in their validation data, where the antibody is pre-incubated with the immunizing peptide. This creates a negative control where specific binding should be abolished, as seen in Western blot and IHC experiments from Boster Bio and Antibodies.com .

• Knockout/knockdown validation: Although not explicitly mentioned in the search results, generating ZNF592 knockdown cells using siRNA or CRISPR-Cas9 would provide definitive evidence of antibody specificity.

• Multiple antibody approach: Use antibodies raised against different epitopes of ZNF592. The search results show antibodies targeting various regions:

  • Abcam's antibody (ab240699) targets amino acids 200-250

  • Boster Bio's antibody (A12580) targets amino acids 961-1010

  • Novus Biologicals' antibody maps to a region between residue 200 and 250

• Recombinant protein testing: Antibodies-online offers recombinant ZNF592 proteins that could be used as positive controls in Western blot experiments .

• Cell line expression validation: Commercial antibodies have been validated in specific cell lines, including HeLa and K562 , which can serve as positive controls in your experiments.

What methodological considerations are important when using ZNF592 antibodies for studying CAMOS and related neurological disorders?

When studying CAMOS (Cerebellar Ataxia with Mental retardation, Optic atrophy and Skin abnormalities) and related neurological disorders using ZNF592 antibodies, consider these methodological approaches:

• Mutation analysis and protein structure studies: The p.Gly1046Arg missense mutation in ZNF592 has been identified in CAMOS patients . Antibodies targeting this region could be useful in studying the structural changes caused by this mutation. Protein homology modeling studies predict this mutation disrupts the zinc finger domain by forming a new hydrogen bond interaction .

• Expression level analysis: Research has shown that ZNF592 transcript levels are higher in CAMOS patients compared to controls. Quantitative RT-PCR showed a three-fold increase in ZNF592 mRNA in a patient homozygous for the p.Gly1046Arg mutation . When designing experiments:

  • Include both homozygous and heterozygous samples when possible

  • Perform experiments in triplicate and repeat with freshly extracted RNA

  • Consider analyzing both mRNA (via qRT-PCR) and protein levels (via Western blot)

• Downstream target analysis: CAMOS patients showed increased levels of cyclin-D1 (CCND1) and cyclin-D2 (CCND2) mRNAs (43-fold and 3-fold increases, respectively) . Consider measuring these downstream targets when studying ZNF592's role in neurological disorders.

• Tissue-specific expression studies: ZNF592 is expressed in various brain regions including the cerebellum, cerebellar vermis, and substantia nigra . For neurological studies, use antibodies validated for brain tissue immunohistochemistry.

• Developmental timing consideration: ZNF592 shows expression during early embryonic development in mouse models , suggesting the importance of analyzing samples from different developmental stages.

What are the optimal conditions for immunohistochemistry using ZNF592 antibodies on different tissue types?

Based on the search results, here are optimal conditions for immunohistochemistry with ZNF592 antibodies:

• Dilution ranges:

  • Novus Biologicals recommends 1:100-1:500 for IHC-Paraffin

  • Boster Bio recommends 1:100-1:300 for IHC

• Tissue types successfully used:

  • Human colon carcinoma tissue (Boster Bio, Antibodies.com)

  • Human breast carcinoma (Novus Biologicals)

  • Human prostate carcinoma (Novus Biologicals)

• Detection methods:

  • DAB (3,3'-diaminobenzidine) staining has been successfully used with Immunohistochemistry Accessory Kits

• Antigen retrieval: While specific conditions aren't detailed in the search results, antigen retrieval is typically necessary for formalin-fixed paraffin-embedded (FFPE) sections.

• Controls:

  • Peptide competition assays provide excellent negative controls, as demonstrated by both Boster Bio and Antibodies.com

  • Consider using tissues with known high expression (e.g., cerebellum, skeletal muscle) as positive controls based on expression data

How do experimental results from ZNF592 antibodies correlate with RNA expression data across different tissues?

The search results provide expression data for ZNF592 at both RNA and protein levels that can be correlated:

• Expression profile correlation:

  • RNA studies using Rapid Scan Gene Expression Panels and northern blot showed ubiquitous expression of ZNF592 in human adult tissues, with higher expression in skeletal muscle and widespread expression in CNS tissues, particularly in the cerebellum, cerebellar vermis, and substantia nigra

  • Lower RNA expression was observed in ovary, uterus, and salivary glands

  • Protein detection via IHC has been validated in several tissue types including breast, prostate, and colon carcinomas

• Methodological approach for correlation studies:

  • Use parallel RNA and protein analysis on the same tissue samples

  • For RNA analysis, consider semi-quantitative RT-PCR as described in the first search result, using β-actin for normalization

  • For protein analysis, use validated ZNF592 antibodies with appropriate controls

  • When comparing results, be aware that protein expression may not always directly correlate with mRNA levels due to post-transcriptional regulation

• Developmental expression:

  • ZNF592 shows expression during early embryonic development in mouse models

  • Semi-quantitative RT-PCR can be used to assess expression in fetal tissues compared to adult tissues

What approaches can resolve contradictory Western blot results when using different ZNF592 antibodies?

When faced with contradictory Western blot results using different ZNF592 antibodies, consider these methodological approaches:

• Epitope mapping and comparison:

  • Compare the epitope regions targeted by different antibodies:

    • Abcam's antibody (ab240699) targets amino acids 200-250

    • Boster Bio's antibody (A12580) targets amino acids 961-1010

  • Antibodies targeting different epitopes may detect different isoforms or post-translationally modified forms of ZNF592

• Comprehensive controls:

  • Include recombinant ZNF592 protein as a positive control

  • Use peptide competition assays for each antibody to confirm specificity

  • Include samples from multiple cell types with known ZNF592 expression (e.g., HeLa, K562)

• Sample preparation optimization:

  • Test different lysis buffers to ensure complete protein extraction

  • Optimize denaturation conditions (temperature, time, reducing agents)

  • Consider native vs. denaturing conditions if protein complexes are suspected

• Molecular weight verification:

  • The calculated molecular weight of ZNF592 is approximately 137-138 kDa

  • Observed molecular weights vary between 72 kDa (Boster Bio) and ~148 kDa (Abcam)

  • Use ladder markers that allow precise molecular weight determination

  • Consider testing pre-stained vs. unstained markers to rule out migration artifacts

• Protocol standardization:

  • Standardize SDS-PAGE conditions (gel percentage, running time, voltage)

  • Use consistent transfer conditions (wet vs. semi-dry, buffer composition, time)

  • Standardize blocking and antibody incubation conditions

How can ZNF592 antibodies be used to investigate the protein's role in transcriptional regulation?

To investigate ZNF592's role in transcriptional regulation using antibodies, consider these methodological approaches:

• Chromatin Immunoprecipitation (ChIP) assays:

  • Use antibodies that have been validated for immunoprecipitation, such as Abcam's antibody (ab240699) or Novus Biologicals' antibody

  • Optimize cross-linking and sonication conditions for efficient chromatin fragmentation

  • Follow with sequencing (ChIP-seq) or PCR (ChIP-PCR) to identify genomic binding sites

• Co-immunoprecipitation (Co-IP) for protein-protein interactions:

  • Use antibodies validated for IP to pull down ZNF592 and identify interacting transcription factors or chromatin modifiers

  • As demonstrated with Abcam's antibody, which successfully immunoprecipitated ZNF592 from HeLa whole cell lysate

• Dual immunofluorescence staining:

  • Use antibodies validated for IF/ICC such as Proteintech's antibody to co-localize ZNF592 with other transcription factors or nuclear markers

  • Analyze co-localization during different cell cycle phases or developmental stages

• Reporter gene assays:

  • Use ZNF592 antibodies to verify protein expression in transfection experiments studying the effect of wild-type vs. mutant ZNF592 on reporter gene activity

• Analysis of downstream targets:

  • Research has shown that CAMOS patients with ZNF592 mutations have increased cyclin-D1 (CCND1) and cyclin-D2 (CCND2) mRNA levels

  • Design experiments to correlate ZNF592 levels (detected by antibodies) with expression of these and other potential downstream targets

• Mutation analysis:

  • The p.Gly1046Arg mutation in ZNF592 is predicted to affect DNA binding by disrupting the eleventh zinc finger domain

  • Compare wild-type and mutant ZNF592 in DNA binding assays, using antibodies to verify protein amounts

How can I troubleshoot weak or non-specific signals when using ZNF592 antibodies in Western blot?

When encountering issues with ZNF592 antibodies in Western blot, consider these troubleshooting approaches:

• Optimize antibody dilution:

  • Manufacturer recommendations vary significantly:

    • Novus Biologicals: 1:2000-1:10000

    • Boster Bio: 1:500-1:2000

  • Test a dilution series to find optimal signal-to-noise ratio for your specific sample

• Sample preparation optimization:

  • Include protease inhibitors to prevent degradation

  • Test different lysis buffers (RIPA, NP-40, etc.)

  • Consider phosphatase inhibitors if studying phosphorylated forms

• Loading control verification:

  • Verify equal loading with housekeeping proteins (β-actin, GAPDH)

  • Consider stain-free gel technology for total protein normalization

• Signal enhancement strategies:

  • Try different detection methods (ECL, fluorescence)

  • Consider signal enhancers compatible with your detection system

  • Optimize exposure times

• Blocking optimization:

  • Test different blocking agents (BSA vs. non-fat dry milk)

  • Optimize blocking time and temperature

• Specificity confirmation:

  • Perform peptide competition assay as demonstrated by Boster Bio and Antibodies.com

  • Use positive control samples (HeLa, K562 cells)

What are the critical considerations when using ZNF592 antibodies for immunofluorescence studies?

For optimal results in immunofluorescence studies with ZNF592 antibodies, consider these methodological factors:

• Fixation method optimization:

  • Compare paraformaldehyde, methanol, or acetone fixation

  • Optimize fixation time to preserve epitope accessibility while maintaining cellular architecture

• Antibody dilution:

  • Proteintech recommends 1:200-1:800 for IF/ICC

  • Boster Bio recommends 1:50-200 for ICC/IF

  • Titrate antibodies to determine optimal concentration for your specific sample

• Permeabilization conditions:

  • Test different permeabilization agents (Triton X-100, saponin, digitonin)

  • Optimize concentration and incubation time

• Signal amplification:

  • Consider tyramide signal amplification for weak signals

  • Use high-sensitivity detection systems for low-abundance targets

• Cell types and positive controls:

  • HeLa cells have been validated as a positive control for ZNF592 IF/ICC studies

  • Compare staining patterns across different cell types

• Co-staining considerations:

  • Use nuclear markers (DAPI, Hoechst) to confirm nuclear localization

  • Consider co-staining with markers of specific nuclear compartments (nucleoli, splicing speckles)

How should I design controls for studying ZNF592 expression in disease models?

When studying ZNF592 expression in disease models, incorporate these controls:

• Antibody validation controls:

  • Peptide competition assay as negative control

  • Include known positive cell lines (HeLa, K562)

• Technical controls:

  • Secondary antibody-only control to assess non-specific binding

  • Isotype control (rabbit IgG) to control for non-specific interactions

  • Loading controls for Western blot (β-actin as used in ZNF592 studies)

• Biological controls:

  • Include tissue/cell samples from both affected and unaffected individuals

  • In studies of CAMOS, include samples from homozygous patients, heterozygous carriers, and wild-type controls as done in previous research

  • Age-matched controls when studying developmental disorders

  • Consider multiple control tissues due to variable expression across tissues

• Expression manipulation controls:

  • Overexpression systems to verify antibody detection limits

  • siRNA or CRISPR knockout/knockdown samples as negative controls

• Quantification controls:

  • Standard curves using recombinant proteins for absolute quantification

  • Housekeeping genes/proteins for relative quantification as demonstrated in previous studies (β-actin)

What are the optimal storage conditions for ZNF592 antibodies to maintain long-term stability?

Based on manufacturer recommendations:

How can I optimize ZNF592 antibody dilutions for different experimental systems?

For optimal ZNF592 antibody dilutions across different applications:

• Western blot optimization:

  • Start with manufacturer recommendations:

    • Novus Biologicals: 1:2000-1:10000

    • Boster Bio: 1:500-1:2000

    • Antibodies.com: 1:500-1:1000

  • Create a dilution series (e.g., 1:500, 1:1000, 1:2000, 1:5000, 1:10000)

  • Assess signal-to-noise ratio at each dilution

  • Consider sample type (cell lysate vs. tissue homogenate) when optimizing

• Immunohistochemistry optimization:

  • Start with manufacturer recommendations:

    • Novus Biologicals: 1:100-1:500

    • Boster Bio: 1:100-1:300

    • Antibodies.com: 1:50-1:100

  • Test dilutions on known positive control tissues

  • Consider tissue fixation method when optimizing (FFPE vs. frozen)

• Immunofluorescence optimization:

  • Start with manufacturer recommendations:

    • Proteintech: 1:200-1:800

    • Boster Bio: 1:50-1:200

  • Test on validated positive control cells (e.g., HeLa)

  • Optimize based on subcellular localization pattern (nuclear expected for ZNF592)

• Methodological approach to optimization:

  • Use consistent lot numbers during optimization

  • Document all variables (antibody dilution, incubation time/temperature, detection method)

  • Quantify signal intensity when possible

  • Consider sample preprocessing (antigen retrieval methods for IHC/IF)

  • Test both freshly prepared and stored diluted antibody